Gender, male/female n (%)
|
39/22 (64/36)
|
Age, all patients, m (SD)
|
61.9 (12.3)
|
Family situation, n (%)
|
Married/cohabitant
|
35 (57)
|
Partner and children
|
11 (18)
|
Single parent
|
3 (5)
|
Single
|
12 (20)
|
Education, n (%)
|
Elementary school
|
15 (25)
|
High school
|
24 (39)
|
University
|
22 (36)
|
Occupational status, n, (%)
|
Working full-time
|
6 (10)
|
Working part-time
|
5 (8)
|
Sickness benefit fulltime
|
17 (28)
|
Retired
|
31 (51)
|
Unemployed
|
1 (2)
|
Other
|
1 (2)
|
Diagnosis, n (%)
|
ALSa
|
31 (51)
|
MNDb
|
23 (38)
|
PLSc
|
7 (12)
|
Time since first symptom of disease, m year (std)
|
5,8 (7.2)
|
Pain, BPI-SFd, n = 55
|
Pain, n = yes (%)
|
41 (74)
|
Pain during past 24 h, n = yes (%)
|
39 (71)
|
Worst level of pain, md (IQR)
|
5.0 (4.5)
|
PSI, n = 41, m (std)
|
3,8 (2,4)
|
Neuropathic pain, n (%), DN4e
|
12 (20)
|
Chronic pain before onset of MND, n (%)
|
22 (36)
|
Disease severity, ALSFRS-Rf, md (Q1-Q3)
|
The bulbar function
|
10 (7,5-12)
|
The fine motor function
|
8 (4-10)
|
The gross motor function
|
7 (5-9)
|
The respiratory function
|
12 (10-12)
|
Drugsg, n (%)
|
Analgetics
|
6 (10)
|
Antidepressants
|
17 (28)
|
Antiepileptics
|
2 (3)
|
Anxiolytics
|
9 (15)
|
Hypnotics
|
16 (26)
|
NSAID
|
8 (13)
|
Opioids
|
7 (12)
|
Spasmolytics
|
6 (10)
|
Triptans
|
2 (3)
|
Riluzole
|
55 (90)
|
Nothing
|
2 (3)
|